Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults
Clinical trial NCT02654080 · COMPLETED
Trial details
- NCT number
- NCT02654080
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-01
- Primary completion
- 2017-08-24
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.